Stocks · News reference
Arrowhead Pharma shares Phase 1/2a data for ARO-MAPT, showing up to 85% tau reduction in central nervous system Alzheimer's disease trial.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injectionARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of 73% on
Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injectionARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of 73% on
The HoFH market is expected to expand through 2036, driven by improved genetic screening, earlier diagnosis, and adoption of targeted lipid-lowering therapies. With approximately 1,840 diagnosed prevalent cases in the 7MM in 2025, the market is shifting toward long-acting, receptor-independent therapies including RNA interference agents and ANGPTL3 inhibitors. Key unmet needs include limited treatment efficacy for patients with minimal LDL receptor function, delayed diagnosis, and high treatment burden.